Effect of cabergoline treatment on Cushing’s disease caused by aberrant adrenocorticotropin-secreting macroadenoma

@article{Miyoshi2004EffectOC,
  title={Effect of cabergoline treatment on Cushing’s disease caused by aberrant adrenocorticotropin-secreting macroadenoma},
  author={Tomoko Miyoshi and Fumio Otsuka and Masaya Takeda and Kenichi Inagaki and Jiro Suzuki and Toshio Ogura and I Date and Kozo Hashimoto and Hiroshi Makino},
  journal={Journal of Endocrinological Investigation},
  year={2004},
  volume={27},
  pages={1055-1059}
}
The present case involves a 47-yr-old woman with Cushing’s disease due to pituitary macroadenoma. The patient had suffered from hypertension and obesity for two yr. Her serum cortisol levels were moderately elevated throughout the observation period, and dexamethasone failed to suppress the cortisol secretion. Plasma ACTH levels were markedly high (>100 pg/ml) and did not respond to CRH provocation. Gel filtration analysis of the patient’s plasma detected the existence of big ACTH molecules… 
Effect of Cabergoline Treatment on Cushing’s Disease Caused by Pituitary Macroadenoma after Incomplete Transsphenoidal Surgery
TLDR
Caberoline (1 mg/wk) was administered for the remnant adenoma, which gradually reduced ACTH levels in 7 days before starting radiation therapy, demonstrating the efficacy of cabergoline to treat Cushing’s disease caused by pituitary macroadenoma.
An extra-adrenal abdominal pheochromocytoma causing ectopic ACTH syndrome.
TLDR
A 55-year-old woman with ectopic adrenocorticotropin (ACTH) secretion caused by extra-adrenal pheochromocytoma is reported, the first report of ectopic ACTH syndrome induced by an extra- adrenal abdominal paraganglioma.
Treatment of Cushing disease: overview and recent findings
TLDR
The aim of this review is to analyze the results and experiences with old and new medical treatments ofCD and to reevaluate medical therapies for complications of CD and hypopituitarism in patients with cured CD.
An unusual case of Cushing's syndrome due to bihormonal ACTH–prolactin secreting pituitary macroadenoma with rapid response to cabergoline
TLDR
A 23-year-old man presenting with florid Cushing's syndrome was found to have high plasma ACTH and very high serum prolactin, and assumes that he most likely has a single bihormonal adenoma that is enriched with dopamine-2 receptors.
Pituitary-directed medical treatment of Cushing’s disease
TLDR
This review focuses on the tumor-directed pharmacological approaches for the management of Cushing’s disease based on the recent identification of possibile targets at a pituitary level.
Medical Treatment in Cushing’s Syndrome: Dopamine Agonists and Cabergoline
TLDR
In conclusion, DA agonists represent a potential preparatory or complementary treatment for endogenous Cushing’s syndrome, especially in Cushing's disease.
Remission with Cabergoline in Adolescent Boys with Cushing’s Disease
TLDR
Two adolescent boys with Cushing’s disease who were treated with cabergoline reached complete remission at the end of the 17th and 24th months, respectively.
A review of Cushing's disease treatment by the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism.
TLDR
It is recommended that patients with CD be followed at tertiary care centers with experience in treating this condition, and cabergoline and ketoconazole are the most commonly used alone or in combination.
Drugs in the medical treatment of Cushing's syndrome
TLDR
There are effective pharmacological agents capable of chronically reversing biochemical and clinical manifestations of hypercortisolemia in Cushing's syndrome but new drugs are needed with action at the pituitary level.
The Treatment of Cushing's Disease.
TLDR
Recent experience suggests that the combination of different drugs may be able to control cortisol excess in a great majority of patients with Cushing's syndrome.
...
1
2
3
...

References

SHOWING 1-10 OF 17 REFERENCES
Pituitary Adenoma Showing Intermittent Secretion of High Molecular Weight Adrenocorticotropin without Evidence of Cushing’s Disease
TLDR
A 29-year-old woman admitted in March 1998 due to high plasma ACTH levels, amenorrhea and uncontrolled diabetes mellitus (DM) which had persisted since 1991 is a very rare form of pituitary adenoma showing intermittent secretion of high molecular ACTH unaccompanied by cushingoid features.
ACTH silent adenoma shrinking under cabergoline.
TLDR
This is the first description of an in vivo shrinkage of an ACTH silent adenoma under cabergoline, and in vitro, the presence of D2 receptors in the primitive tumor in concentrations similar to those found in control prolactinomas is demonstrated.
Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline
TLDR
It is demonstrated that cabergoline treatment is able to induce the remission of Nelson’s syndrome and may be a valid therapeutic alternative in this syndrome.
Cushing's disease: a comparison of pituitary corticotroph microadenomas and macroadenomas.
TLDR
In comparison with microadenomas, corticotroph macroadenomas are characterized by a greater and more autonomous ACTH secretion, inducing more pronounced biological signs of hypercorticism, and are more often accompanied by visual field defects and impairment of other pituitary hormonal secretions.
Macroprolactinoma associated with Cushing’s disease, successfully treated with cabergoline
TLDR
A 31-yr-old man affected with a macroprolactinoma associated with a florid clinical image of Cushing’s disease received medical treatment with cabergoline only, avoiding pituitary surgery and radiotherapy in this type of tumor.
Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
TLDR
In summary, corticotroph macroadenomas are often associated with less glucocorticoid suppressibility than the more frequently occurring microadenomas and may be a more sensitive indicator of neoplastic findings in patients with Cushing's disease.
Successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma.
TLDR
Gonadotroph microadenoma should be considered in women with spontaneous ovarian hyperstimulation, even if they have no neurological symptoms or marked pituitary enlargement, and bromocriptine therapy may be an alternative to pituitsary surgery.
Management of Pituitary Tumors
TLDR
This review focuses on therapeutic options currently available for pituitary tumors, especially for large, invasive adenomas, and recommends a dopamine agonist (cabergoline or bromocriptine) should be the initial therapy in patients with either microprolactinomas or macroprolACTinomas.
Cabergoline in the treatment of acromegaly: a study in 64 patients.
TLDR
The results of this study suggest that cabergoline is an effective, well tolerated therapy that should be considered in the management of acromegaly, especially if the pituitary adenoma cosecretes GH and PRL or if pretreatment plasma IGF-I levels are below 750 micrograms/L.
Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
TLDR
The high efficacy and tolerability of cabergoline in the treatment of pathological hyperprolactinemia is confirmed, in a large-scale retrospective study, leaving few patients with unacceptable side effects or inadequate clinical response.
...
1
2
...